A Pilot Study of Oncaspar® + Dexamethasone in Patients With Relapsed or Refractory T-Cell Lymphoma
Status:
Terminated
Trial end date:
2017-02-01
Target enrollment:
Participant gender:
Summary
This is an open-label, single-arm pilot study of Oncaspar® with dexamethasone for patients
with relapsed or refractory peripheral T-cell lymphoma (PTCL), excluding extranodal NK/T cell
lymphoma (ENKTL). Patients will receive up to 8 courses of treatment.
Phase:
Early Phase 1
Details
Lead Sponsor:
Dana-Farber Cancer Institute
Collaborators:
Leadiant Biosciences, Inc. Sigma Tau Pharmaceuticals, Inc.